

Zvezdan Pirtosek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5027004/publications.pdf>

Version: 2024-02-01

71
papers

1,661
citations

331670

21
h-index

302126

39
g-index

75
all docs

75
docs citations

75
times ranked

2215
citing authors

#	ARTICLE	IF	CITATIONS
1	Euro<sc>I</sc>nf: <sc>A</sc> <sc>M</sc>ulticenter <sc>C</sc>omparative <sc>O</sc>bservational <sc>S</sc>tudy of <sc>A</sc>pomorphine and <sc>L</sc>evodopa <sc>I</sc>nfusion in <sc>P</sc>arkinson's <sc>D</sc>isease. Movement Disorders, 2015, 30, 510-516.	3.9	203
2	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
3	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Movement Disorders, 2019, 34, 353-365.	3.9	126
4	Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Movement Disorders, 2005, 20, 937-944.	3.9	113
5	The diabetic brain and cognition. Journal of Neural Transmission, 2017, 124, 1431-1454.	2.8	77
6	Characterizing advanced Parkinsonâ€™s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 2019, 19, 50.	1.8	74
7	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2018, 4, 14.	5.3	70
8	Abnormal metabolic brain network associated with Parkinsonâ€™s disease: replication on a new European sample. Neuroradiology, 2017, 59, 507-515.	2.2	55
9	An updated diagnostic approach to subtype definition of vascular parkinsonism â€“ Recommendations from an expert working group. Parkinsonism and Related Disorders, 2018, 49, 9-16.	2.2	55
10	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51
11	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. Annals of Neurology, 2001, 50, 567-573.	5.3	39
12	Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease. Frontiers in Pharmacology, 2019, 10, 8.	3.5	39
13	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
14	Light chain deposition disease restricted to the brain: the first case report. Human Pathology, 2007, 38, 179-184.	2.0	34
15	Update on the Management of Parkinsonâ€™s Disease for General Neurologists. Parkinson's Disease, 2020, 2020, 1-13.	1.1	33
16	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.8	32
17	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	3.6	32
18	Gene expression changes in blood as a putative biomarker for Huntington's disease. Movement Disorders, 2009, 24, 2277-2281.	3.9	28

#	ARTICLE	IF	CITATIONS
19	Processing complex pseudo-words in mild cognitive impairment: The interaction of preserved morphological rule knowledge with compromised cognitive ability. <i>Clinical Linguistics and Phonetics</i> , 2016, 30, 49-67.	0.9	28
20	The syndrome of deafness–dystonia: Clinical and genetic heterogeneity. <i>Movement Disorders</i> , 2013, 28, 795-803.	3.9	25
21	Similar effect of intermittent theta burst and sham stimulation on corticospinal excitability: A 5–day repeated sessions study. <i>European Journal of Neuroscience</i> , 2018, 48, 1990-2000.	2.6	25
22	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns–based approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2901-2910.	6.4	23
23	Dopaminergic medication alters auditory distractor processing in Parkinson's disease. <i>Acta Psychologica</i> , 2015, 156, 45-56.	1.5	22
24	Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson–s disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 50.	7.2	22
25	Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 13-16.	2.2	21
26	Elicitation of neurological knowledge with argument-based machine learning. <i>Artificial Intelligence in Medicine</i> , 2013, 57, 133-144.	6.5	18
27	Cardiovascular reflexes in Parkinson's disease: Effect of domperidone and apomorphine. <i>Clinical Autonomic Research</i> , 1992, 2, 215-219.	2.5	17
28	Tremor amplitude and tremor frequency variability in Parkinson–s disease is dependent on activity and synchronisation of central oscillators in basal ganglia. <i>Medical Hypotheses</i> , 2010, 74, 362-365.	1.5	15
29	The P3 cognitive ERP has at least some sensory modality–specific generators: Evidence from high–resolution EEG. <i>Psychophysiology</i> , 2017, 54, 416-428.	2.4	14
30	Sex differences in Parkinson's disease: A transcranial magnetic stimulation study. <i>Movement Disorders</i> , 2019, 34, 1873-1881.	3.9	14
31	Event-related potentials elicited by distractors in an auditory oddball paradigm in schizophrenia. <i>Psychiatry Research</i> , 2005, 137, 49-59.	3.3	13
32	Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other Î±-Synucleinopathies. <i>Frontiers in Neurology</i> , 2019, 10, 1204.	2.4	13
33	Postural stability under globus pallidus internus stimulation for dystonia. <i>Clinical Neurophysiology</i> , 2015, 126, 2299-2305.	1.5	11
34	Suicide in Parkinson's disease patients treated with levodopa–carbidopa intestinal gel. <i>Movement Disorders</i> , 2015, 30, 1434-1435.	3.9	10
35	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017, 8, 44-53.	1.3	10
36	The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson–s disease. <i>Physica Medica</i> , 2018, 52, 104-112.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 106, 37-44.	3.1	10
38	Botulinum Toxin in the Treatment of Neurological Disorders. <i>Annals of the New York Academy of Sciences</i> , 1994, 710, 76-87.	3.8	9
39	Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra. <i>Brain Sciences</i> , 2019, 9, 335.	2.3	9
40	Neuroprotection and Dopamine Agonists. <i>Advances in Experimental Medicine and Biology</i> , 2004, , 55-74.	1.6	8
41	Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2022, 16, 118-129.	2.1	7
42	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. <i>Biomedicine Hub</i> , 2020, 5, 1-22.	1.2	7
43	A case of multiple system atrophy with normal dopamine transporter imaging. <i>Journal of Neurology</i> , 2012, 259, 2729-2731.	3.6	6
44	Sensory Trick in Levodopa-induced Orolingual Dystonia in a Patient with Advanced Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 136-137.	1.5	4
45	Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 1-3.	2.2	4
46	Cognition in late onset depression. <i>Psychiatry Research</i> , 2013, 210, 89-94.	3.3	3
47	Identification and validation of Alzheimer's disease-related metabolic pattern in patients with pathologically confirmed Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042629.	0.8	3
48	Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 167-176.	2.1	3
49	Wavelet Analysis Increases Sensitivity and Specificity of Spirography for Ambulatory Tremor Discrimination. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	2
50	Preserved cholinergic forebrain integrity reduces structural connectome vulnerability in mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2021, 425, 117443.	0.6	2
51	ABML Knowledge Refinement Loop: A Case Study. <i>Lecture Notes in Computer Science</i> , 2012, , 41-50.	1.3	2
52	Elicitation of Neurological Knowledge with ABML. <i>Lecture Notes in Computer Science</i> , 2011, , 14-23.	1.3	2
53	Headache Because of Problems with Teeth, Mouth, Jaws, or Dentures in Chronic Temporomandibular Disorder Patients: A Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3052.	2.6	2
54	P2-093: THE ROLE OF NEUROPSYCHOLOGICAL ASSESSMENT IN PREDICTING CSF DEMENTIA MEASURES IN MILD COGNITIVE IMPAIRMENT. , 2014, 10, P505-P505.		1

#	ARTICLE	IF	CITATIONS
55	IC-P-078: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P56-P57.		1
56	Hypometric anticipatory postural adjustments in dystonia are not affected by deep brain stimulation of globus pallidus internus. Neuroscience Letters, 2017, 636, 151-157.	2.1	1
57	[P1â€“391]: MONITORING THE PROGRESSION OF DEMENTIA USING FDGâ€“PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER'S DISEASEâ€“RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P416.	0.8	1
58	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. Annals of Neurology, 2001, 50, 567.	5.3	1
59	Abnormal metabolic brain network in behavioral variant of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	1
60	IC-P-146: THE ASSOCIATION BETWEEN CSF AND FDG/PET IMAGING BIOMARKERS OF NEURODEGENERATION IN MILD COGNITIVE IMPAIRMENT. , 2014, 10, P84-P84.		0
61	Blurred boundaries between organic and functional etiology: A man with a jerky leg. Journal of the Neurological Sciences, 2015, 354, 122-123.	0.6	0
62	P3-152: Correlation between metabolic and CSF biomarkers in Alzheimer's disease patients with early cognitive decline. , 2015, 11, P685-P686.		0
63	P1-252: Characteristic Metabolic Brain Pattern in Slovenian Alzheimer's Disease Patients with Low CSF Beta-Amyloid. , 2016, 12, P505-P506.		0
64	[ICâ€“Pâ€“035]: MONITORING THE PROGRESSION OF DEMENTIA USING FDGâ€“PET BRAIN IMAGING AND NETWORK ANALYSIS: ROLE OF THE ALZHEIMER'S DISEASEâ€“RELATED PATTERN. Alzheimer's and Dementia, 2017, 13, P31.	0.8	0
65	[ICâ€“Pâ€“025]: THALAMIC CONNECTIVITY CONTRIBUTES TO EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P24.	0.8	0
66	[P2â€“299]: THALAMIC CONNECTIVITY CONTRIBUTES TO EPISODIC MEMORY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P731.	0.8	0
67	ICâ€“Pâ€“045: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P45.	0.8	0
68	P3â€“364: SIMILAR METABOLIC BRAIN CHARACTERISTICS OF DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1227.	0.8	0
69	Preserved cholinergic forebrain structure reduces the impact of strategic lesions to the connectome in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e043882.	0.8	0
70	Family history based approach in risk prediction for Parkinson's disease: Additional contribution of familial associated disorders. Genetika, 2015, 47, 303-310.	0.4	0
71	Progression of metabolic brain patterns in common dementias. Alzheimer's and Dementia, 2021, 17, .	0.8	0